ANNOUNCEMENT NO. 279

October 16, 2024

Updated turnover and operating profit forecasts

ChemoMetec maintained its positive performance in the first quarter of 2024/25 with better than expected sales and order intake.

On this basis, the company now expects revenue for the 2024/25 financial year to be between DKK 445 million and DKK 460 million, compared to DKK 435 million to DKK 450 million in the most recent forecast, and EBITDA to be between 222 and 230 million DKK, increasing. compared to 216-223 million DKK previously.

ChemoMetec’s interim report for the first quarter 2024/25 is expected to be published on Thursday, November 7, 2024.

Additional Information

Martin Helbo Behrens, CEO
Such. : (+45) 48 13 10 20

Kim Nicolajsen, financial director
Such. : (+45) 48 13 10 20

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec instruments are marketed to the pharmaceutical, biotechnology and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s largest pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, visit www.chemometec.com.